Nasal High Flow Therapy 30 Day Readmission Study

Stopped early · Not applicable

Conditions studied: Chronic Obstructive Pulmonary Disease, COPD

In brief

The aim of this feasibility study is to provide data for a subsequent randomized controlled trial to investigate if patient outcomes will be improved after an acute COPD exacerbation using domiciliary nasal high flow therapy (NHF) compared to standard care. This feasibility study will investigate the following: process, resources, management and scientific aspects of delivering NHF as an adjunct therapy in COPD patients.

Key facts

Study ID

NCT02552732

Run by

Fisher and Paykel Healthcare

People needed

29

Starts

2015-11-01

Expected to finish

2017-05-03

Last updated by the study team

2020-08-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• Male and female
• Admitted to the respiratory ward(s) of either recruiting hospitals with AECOPD as the primary diagnostic reason for admission.

You may not qualify if…

• Given a new home oxygen therapy prescription during the current hospital admission
• The investigator believes the participant or their care giver will be unable to safely use the myAIRVO 2 device following discharge
• They have any other condition which, at the investigator's discretion, is believed may present a safety risk or impact the feasibility of the study or the study results

Where it is running

• Alana HealthCare — Liverpool, New York, United States
• Medical Research Institute of New Zealand — Wellington, New Zealand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.